Almost all previous clinical trials and retrospective studies suggest the use of pertuzumab in addition to the use of trastuzumab in neoadjuvant settings for HER2-positive breast cancer female patients to achieve a better pCR. This evidence concerns the gene ERBB2 and breast cancer.